Clinical Trials Using Recombinant EphB4-HSA Fusion Protein

Clinical trials are research studies that involve people. The clinical trials on this list are studying Recombinant EphB4-HSA Fusion Protein. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-6 of 6
  • Recombinant EphB4-HSA Fusion Protein and Pembrolizumab in Treating Patients with Metastatic or Recurrent Urothelial Cancer That Is Refractory to Certain Chemotherapy Drugs

    This phase II trial studies how well recombinant EphB4-HSA fusion protein and pembrolizumab work in treating patients with urothelial (bladder) cancer that has spread from the primary site to other places in the body or has come back and does not respond to certain chemotherapy drugs. Combinations of biological substances in recombinant EphB4-HSA fusion protein may be able to carry tumor-killing substances directly to urothelial cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving recombinant EphB4-HSA fusion protein and pembrolizumab together may be a better treatment for patients with urothelial cancer.
    Location: 6 locations

  • sEphB4-HSA in Treating Patients with Kaposi Sarcoma

    This phase II trial studies recombinant EphB4-HSA fusion protein (sEphB4-HSA) in treating patients with Kaposi sarcoma. Recombinant EphB4-HSA fusion protein may block the growth of blood vessels that provide blood to the cancer, and may also prevent cancer cells from growing.
    Location: 10 locations

  • Recombinant EphB4-HSA Fusion Protein and Pembrolizumab in Treating Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer or Locally Recurrent or Metastatic Head and Neck Squamous Cell Cancer

    This phase IIa trial studies how well recombinant EphB4-HSA fusion protein and pembrolizumab work in treating patients with non-small cell lung cancer that has spread to other places in the body or head and neck squamous cell cancer that has come back or spread to other places in the body. Recombinant EphB4-HSA fusion protein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Giving recombinant EphB4-HSA fusion protein and pembrolizumab may work better in treating patients with non-small cell lung or head and neck squamous cell cancer.
    Location: 3 locations

  • sEphB4-HSA in Combination with Chemotherapy or Cetuximab and Radiation Therapy for the Treatment of High Risk, Stage III-IVB Head and Neck Squamous Cell Carcinoma

    This phase I / Ib trial studies the side effects and best dose of sEphB4-HSA when given together with chemotherapy or cetuximab and radiation therapy in treating patients with high risk, stage III-IVB head and neck squamous cell carcinoma. sEphB4-HSA works by blocking one way tumors get a blood supply. Chemotherapy drugs, such as cisplatin or carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as cetuximab, may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving sEphB4-HSA with chemotherapy or cetuximab and radiation therapy may work better in treating patients with head and neck squamous cell carcinoma compared to cetuximab and radiation therapy alone.
    Location: University of Colorado, Denver, Colorado

  • sEphB4-HSA in Treating Patients with Metastatic Castration-Resistant Prostate Cancer

    The purpose of this phase II, single-arm, open-label, three center study is to evaluate the efficacy, safety, and tolerability of sEphB4-HSA in patients with mCRPC (metastatic castration-resistant prostate cancer). The study drug, sEphB4-HAS, is a form of protein that has not been approved for sale by the United States Food and Drug Administration (FDA). The study drug prevents tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor.
    Location: 3 locations

  • sEphB4-HSA in Treating Participants with BCG-Unresponsive or Refractory Bladder Cancer

    This phase I trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein (sEphB4-HSA), and to see how well it works in treating participants with bladder cancer that has come back or that isn't responding to bacillus Calmette-Guerin (BCG) vaccine treatment. sEphB4-HAS prevents tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. Giving sEphB4-HSA may work better in treating participants with bladder cancer.
    Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California